JP5241729B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP5241729B2 JP5241729B2 JP2009537359A JP2009537359A JP5241729B2 JP 5241729 B2 JP5241729 B2 JP 5241729B2 JP 2009537359 A JP2009537359 A JP 2009537359A JP 2009537359 A JP2009537359 A JP 2009537359A JP 5241729 B2 JP5241729 B2 JP 5241729B2
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- compound
- mmol
- tert
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *[C@](C(N(CC(*)(*)C1)[C@@]1C(NC(C1)(C1*1S=O)C1=O)=O)=O)N Chemical compound *[C@](C(N(CC(*)(*)C1)[C@@]1C(NC(C1)(C1*1S=O)C1=O)=O)=O)N 0.000 description 7
- MCHJEWAZSNQQMN-UHFFFAOYSA-N C1C=CC(c2ccccc2)=CC1 Chemical compound C1C=CC(c2ccccc2)=CC1 MCHJEWAZSNQQMN-UHFFFAOYSA-N 0.000 description 1
- OLOQYLMGZNLROI-IADCTJSHSA-N CC(C)(C)N(CC(C)(C)CC(N(C[C@@](C1)(c(cc2)ccc2-c2ccccc2)OC)[C@@H]1C(O)=O)=O)C(N)=O Chemical compound CC(C)(C)N(CC(C)(C)CC(N(C[C@@](C1)(c(cc2)ccc2-c2ccccc2)OC)[C@@H]1C(O)=O)=O)C(N)=O OLOQYLMGZNLROI-IADCTJSHSA-N 0.000 description 1
- FVVKCIUZDXQPKF-UHFFFAOYSA-N CC(C)(C)NS(C1(C)CC1)(=O)=O Chemical compound CC(C)(C)NS(C1(C)CC1)(=O)=O FVVKCIUZDXQPKF-UHFFFAOYSA-N 0.000 description 1
- UVVFHPGTZBISKS-JXFKEZNVSA-N CC(C)(C)OC(N(C[C@@](C1)(c2cc3ccccc3cc2)O)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@](C1)(c2cc3ccccc3cc2)O)[C@@H]1C(O)=O)=O UVVFHPGTZBISKS-JXFKEZNVSA-N 0.000 description 1
- BIUSYVKYHHYRLB-LRDDRELGSA-N CC(C)(C)OC(N(C[C@@](C1)(c2ccccc2)O)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@](C1)(c2ccccc2)O)[C@@H]1C(O)=O)=O BIUSYVKYHHYRLB-LRDDRELGSA-N 0.000 description 1
- NBXGDPBFRRQZEV-UHFFFAOYSA-N CC(C)(C)OC(NS(C1CC1)(=O)=O)=O Chemical compound CC(C)(C)OC(NS(C1CC1)(=O)=O)=O NBXGDPBFRRQZEV-UHFFFAOYSA-N 0.000 description 1
- XUMZAMWDKOPMEO-SWFZTDOFSA-N CC(C)(C)[C@@H](C(N(CC(C1)=O)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O Chemical compound CC(C)(C)[C@@H](C(N(CC(C1)=O)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O XUMZAMWDKOPMEO-SWFZTDOFSA-N 0.000 description 1
- XYXBVELFAOEJDK-OUAUKWLOSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(O)=O)=O)NC(OC(C)(C)C)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(O)=O)=O)NC(OC(C)(C)C)=O XYXBVELFAOEJDK-OUAUKWLOSA-N 0.000 description 1
- CKOJURFJIHANTR-NVQLVTCGSA-N CC(C)(C)[C@@H](C(N(C[C@@](C1)(c(cc2)ccc2-c2ccccc2OC)O)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@](C1)(c(cc2)ccc2-c2ccccc2OC)O)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(NS(C1CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O CKOJURFJIHANTR-NVQLVTCGSA-N 0.000 description 1
- MAIOIHOZWCCVGK-DWACAAAGSA-N CC(C)(CC(N(C[C@@](C1)(c(cc2)ccc2-c2ccccc2)OC)[C@@H]1C(N)=O)=O)C[O](C(C)(C)C(F)(F)F)C(N)=O Chemical compound CC(C)(CC(N(C[C@@](C1)(c(cc2)ccc2-c2ccccc2)OC)[C@@H]1C(N)=O)=O)C[O](C(C)(C)C(F)(F)F)C(N)=O MAIOIHOZWCCVGK-DWACAAAGSA-N 0.000 description 1
- AGHMCMIIWUWTTE-OHUTUQOASA-N CC(CC(N(CC(C1)(c(cc2)ccc2-c2ccccc2)OC)[C@@H]1C(O)=O)=O)C(C)[O](C(C)(C)C)C(N)=O Chemical compound CC(CC(N(CC(C1)(c(cc2)ccc2-c2ccccc2)OC)[C@@H]1C(O)=O)=O)C(C)[O](C(C)(C)C)C(N)=O AGHMCMIIWUWTTE-OHUTUQOASA-N 0.000 description 1
- KHEZKDIWDCVMTL-UHFFFAOYSA-N CCCNC(C1(CC1)S(N)(=O)=O)=O Chemical compound CCCNC(C1(CC1)S(N)(=O)=O)=O KHEZKDIWDCVMTL-UHFFFAOYSA-N 0.000 description 1
- OPASRWWZEIMSOZ-UHFFFAOYSA-N NS(C1CCCC1)(=O)=O Chemical compound NS(C1CCCC1)(=O)=O OPASRWWZEIMSOZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86613006P | 2006-11-16 | 2006-11-16 | |
| US60/866,130 | 2006-11-16 | ||
| US11/939,780 | 2007-11-14 | ||
| US11/939,780 US7888464B2 (en) | 2006-11-16 | 2007-11-14 | Hepatitis C virus inhibitors |
| PCT/US2007/084799 WO2008064066A1 (en) | 2006-11-16 | 2007-11-15 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510234A JP2010510234A (ja) | 2010-04-02 |
| JP2010510234A5 JP2010510234A5 (OSRAM) | 2010-12-24 |
| JP5241729B2 true JP5241729B2 (ja) | 2013-07-17 |
Family
ID=39247306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537359A Expired - Fee Related JP5241729B2 (ja) | 2006-11-16 | 2007-11-15 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7888464B2 (OSRAM) |
| EP (1) | EP2086995B1 (OSRAM) |
| JP (1) | JP5241729B2 (OSRAM) |
| KR (1) | KR20090083462A (OSRAM) |
| AT (1) | ATE546460T1 (OSRAM) |
| AU (1) | AU2007323793A1 (OSRAM) |
| BR (1) | BRPI0719008A2 (OSRAM) |
| CA (1) | CA2669856A1 (OSRAM) |
| CO (1) | CO6190510A2 (OSRAM) |
| EA (1) | EA015827B1 (OSRAM) |
| ES (1) | ES2381308T3 (OSRAM) |
| IL (1) | IL198741A0 (OSRAM) |
| MX (1) | MX2009004943A (OSRAM) |
| NO (1) | NO20091871L (OSRAM) |
| NZ (1) | NZ576814A (OSRAM) |
| WO (1) | WO2008064066A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| CA2676297A1 (en) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim International Gmbh | Inhibitors of hepatitis c ns3 protease |
| JP5647790B2 (ja) * | 2007-11-16 | 2015-01-07 | 株式会社カネカ | Ｎ−カルバモイル−ｔｅｒｔ−ロイシンの製造法 |
| CN101977621A (zh) * | 2007-12-05 | 2011-02-16 | 益安药业 | 氟化三肽hcv丝氨酸蛋白酶抑制剂 |
| MX2010008109A (es) * | 2008-01-24 | 2010-09-22 | Enanta Pharm Inc | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). |
| JP5490778B2 (ja) * | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) * | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) * | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100272674A1 (en) * | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8283310B2 (en) * | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| EP2448912A4 (en) * | 2009-07-02 | 2014-05-28 | Reddys Lab Ltd Dr | ENZYMES AND METHODS FOR DEDOLDING AMINOVINYL-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES |
| US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
| JP5568137B2 (ja) * | 2010-09-22 | 2014-08-06 | 三井化学アグロ株式会社 | 含フッ素カルバマート基を有するアミノ酸アミド誘導体の製造方法、その製造中間体、及びエチレンジアミン誘導体の製造方法 |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
| MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| WO2013190509A2 (en) * | 2012-06-22 | 2013-12-27 | Dr.Reddys Laboratories Limited | Preparation of intermediates of boceprevir |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
| CN103396344B (zh) * | 2013-08-08 | 2014-10-29 | 苏州永健生物医药有限公司 | 一锅法合成n-叔丁氨羰基-3-甲基-l-缬氨酸的方法 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0475255A3 (en) | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
| UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| EP1003775B1 (en) | 1997-08-11 | 2005-03-16 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
| IL134233A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide analogues |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CN1498224A (zh) | 2000-07-21 | 2004-05-19 | ���鹫˾ | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| HUP0500456A3 (en) | 2000-11-20 | 2012-05-02 | Bristol Myers Squibb Co | Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US6869964B2 (en) | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
| WO2004043339A2 (en) | 2002-05-20 | 2004-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| US7041698B2 (en) | 2002-05-20 | 2006-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| CN1771050A (zh) | 2003-02-07 | 2006-05-10 | 益安药业 | 丙型肝炎丝氨酸蛋白酶的大环抑制剂 |
| WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| CA2516018C (en) | 2003-03-05 | 2011-08-23 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| BRPI0409068A (pt) | 2003-04-02 | 2006-03-28 | Boehringer Ingelheim Int | composições farmacêuticas para inibidores de protease viral de hepatite c. |
| DE602004019518D1 (de) | 2003-04-16 | 2009-04-02 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| EP2143727B1 (en) | 2003-04-18 | 2015-01-21 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| DE602004010137T2 (de) | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
| WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| AU2004274051A1 (en) | 2003-09-22 | 2005-03-31 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| MXPA06004006A (es) | 2003-10-10 | 2006-06-28 | Vertex Pharma | Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c. |
| CN103145715B (zh) | 2003-10-14 | 2016-08-03 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2005051980A1 (en) | 2003-11-20 | 2005-06-09 | Schering Corporation | Depeptidized inhibitors of hepatitis c virus ns3 protease |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP4682155B2 (ja) | 2004-01-21 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスに対して活性な大環状ペプチド |
| SI1713823T1 (sl) | 2004-01-30 | 2010-04-30 | Medivir Ab | Inhibitorji HCV NS-3 serin proteaze |
| WO2005095403A2 (en) | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
| JP5156374B2 (ja) | 2004-05-25 | 2013-03-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 非環式ｈｃｖプロテアーゼインヒビターの調製方法 |
| EP1763531A4 (en) | 2004-06-28 | 2009-07-01 | Boehringer Ingelheim Int | ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES |
| EP2316839B1 (en) | 2004-07-16 | 2014-03-12 | Gilead Sciences, Inc. | Antiviral heterocyclic compounds having phosphonate groups |
| CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| WO2006026352A1 (en) | 2004-08-27 | 2006-03-09 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
| CA2577831A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| EP1805187A1 (en) | 2004-10-21 | 2007-07-11 | Pfizer, Inc. | Inhibitors of hepatitis c virus protease, and compositions and treatments using the same |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2006096652A2 (en) | 2005-03-08 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| US20060276406A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20060281689A1 (en) | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| ES2572980T3 (es) | 2005-06-02 | 2016-06-03 | Merck Sharp & Dohme Corp. | Combinación de inhibidores de la proteasa del VHC con un tensioactivo |
| WO2006130554A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| WO2006130686A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors in combination with food |
| WO2006130688A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Compounds for inhibiting cathepsin activity |
| WO2006130687A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
| WO2006130627A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis c |
| WO2006130607A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| WO2006130553A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
| EP1910378B1 (en) | 2005-07-20 | 2012-06-20 | Boehringer Ingelheim International GmbH | Hepatitis c inhibitor peptide analogs |
| GEP20105124B (en) | 2005-07-25 | 2010-11-25 | Array Biopharma Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| DE602006019883D1 (de) | 2005-07-29 | 2011-03-10 | Medivir Ab | Makrocyclische inhibitoren des hepatitis-c-virus |
| ES2389964T3 (es) | 2005-07-29 | 2012-11-05 | Janssen R&D Ireland | Inhibidores macrocíclicos del virus de la hepatitis C |
| AU2006274862B2 (en) | 2005-07-29 | 2012-03-22 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
| JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
| WO2007017144A2 (en) | 2005-07-29 | 2007-02-15 | Medivir Ab | Macrocylic inhibitors of hepatitis c virus |
| PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| DK1912997T3 (da) | 2005-07-29 | 2012-01-02 | Tibotec Pharm Ltd | Makrocycliske inhibitorer af hepatitis C virus |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| JP5171624B2 (ja) | 2005-07-29 | 2013-03-27 | テイボテク・フアーマシユーチカルズ | Ｃ型肝炎ウイルスの大環状阻害剤 |
| US8183277B2 (en) | 2005-07-29 | 2012-05-22 | Tibotec Pharmaceuticals Ltd. | Macrocylic inhibitors of hepatitis C virus |
| EP1915382A2 (en) | 2005-08-01 | 2008-04-30 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
| JP4705984B2 (ja) | 2005-08-01 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| UA93990C2 (ru) | 2005-10-11 | 2011-03-25 | Интермюн, Инк. | Соединения и способ ингибирования репликации вируса гепатита c |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| US20090220457A1 (en) | 2006-03-03 | 2009-09-03 | Lahser Frederick C | Combinations comprising hcv protease inhibitor(s) and hcv ires inhibitor(s), and methods of treatment related thereto |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
-
2007
- 2007-11-14 US US11/939,780 patent/US7888464B2/en active Active
- 2007-11-15 EA EA200900697A patent/EA015827B1/ru not_active IP Right Cessation
- 2007-11-15 BR BRPI0719008-5A2A patent/BRPI0719008A2/pt not_active IP Right Cessation
- 2007-11-15 ES ES07864446T patent/ES2381308T3/es active Active
- 2007-11-15 AU AU2007323793A patent/AU2007323793A1/en not_active Abandoned
- 2007-11-15 KR KR1020097012336A patent/KR20090083462A/ko not_active Withdrawn
- 2007-11-15 NZ NZ576814A patent/NZ576814A/en not_active IP Right Cessation
- 2007-11-15 AT AT07864446T patent/ATE546460T1/de active
- 2007-11-15 MX MX2009004943A patent/MX2009004943A/es active IP Right Grant
- 2007-11-15 JP JP2009537359A patent/JP5241729B2/ja not_active Expired - Fee Related
- 2007-11-15 CA CA002669856A patent/CA2669856A1/en not_active Abandoned
- 2007-11-15 EP EP07864446A patent/EP2086995B1/en active Active
- 2007-11-15 WO PCT/US2007/084799 patent/WO2008064066A1/en not_active Ceased
-
2009
- 2009-05-13 NO NO20091871A patent/NO20091871L/no not_active Application Discontinuation
- 2009-05-14 IL IL198741A patent/IL198741A0/en unknown
- 2009-05-15 CO CO09049882A patent/CO6190510A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007323793A1 (en) | 2008-05-29 |
| MX2009004943A (es) | 2009-05-19 |
| CO6190510A2 (es) | 2010-08-19 |
| NO20091871L (no) | 2009-07-31 |
| EA200900697A1 (ru) | 2010-02-26 |
| US7888464B2 (en) | 2011-02-15 |
| KR20090083462A (ko) | 2009-08-03 |
| EA015827B1 (ru) | 2011-12-30 |
| JP2010510234A (ja) | 2010-04-02 |
| CA2669856A1 (en) | 2008-05-29 |
| WO2008064066A1 (en) | 2008-05-29 |
| EP2086995A1 (en) | 2009-08-12 |
| EP2086995B1 (en) | 2012-02-22 |
| ES2381308T3 (es) | 2012-05-25 |
| ATE546460T1 (de) | 2012-03-15 |
| HK1128131A1 (en) | 2009-10-16 |
| IL198741A0 (en) | 2010-02-17 |
| BRPI0719008A2 (pt) | 2013-12-03 |
| NZ576814A (en) | 2011-06-30 |
| US20090274648A1 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5241729B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5221552B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド | |
| JP5241728B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド | |
| JP5450604B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP4940231B2 (ja) | Ｃ型肝炎ウイルスインヒビターとしてのトリペプチド | |
| JP5512655B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| US7935670B2 (en) | Hepatitis C virus inhibitors | |
| JP5474940B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2012512169A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2010508362A (ja) | Ｃ型肝炎ウイルスの阻害剤 | |
| JP2010508361A (ja) | Ｃ型肝炎ウイルスの阻害剤 | |
| JP2010508360A (ja) | Ｃ型肝炎ウイルスの阻害剤 | |
| JP6110846B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド | |
| JP2011521911A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| CN101568543B (zh) | 大环肽作为丙型肝炎病毒抑制剂 | |
| CN101568336B (zh) | 大环肽在制备丙型肝炎病毒抑制剂中的用途 | |
| HK1128131B (en) | Hepatitis c virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101105 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130312 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130402 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160412 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |